Category Archives: Public Policy

Latest From Public Policy

Patent Reform Legislation Off The Table For Now

Williams

If the mainstream media is to be believed, the patent system is broken.  This notion is frequently blamed on the perceived increase in so-called patent assertion entities (“PAEs”), referred to derogatorily as “patent trolls.”  More often than not, these media reports cite to a limited number of examples illustrating the perceived abuses, and reach the conclusion that patents are stifling innovation.  And, even though there has been serious disagreement about the extent of the problem, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Supreme Court Decision on Web Content Delivery to Impact Biotech Patents

Zuhn

Earlier this month, in Limelight Networks, Inc. v. Akamai Technologies, Inc., the Supreme Court issued a decision that will likely impact patents directed to methods for treating or diagnosing diseases.  In Limelight Networks, the Court reversed the appellate court’s finding that Limelight had infringed U.S. Patent No. 6,108,703, which is assigned to the Massachusetts Institute of Technology and is exclusively licensed to Akamai Technologies.  In particular, the Court determined that a defendant is not liable Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

IP at the 2014 BIO International Convention

San Diego

Securing and maintaining intellectual property protection for the next generation of biotech innovation faces new challenges and opportunities.  Come learn about current issues and those just on the horizon before they affect your practice and your company. Keynote Speakers in the IP Track: Director General Francis Gurry, World Intellectual Property Organization Judge Randall R. Rader, United States Court of Appeals for the Federal Circuit Acting Director Michelle Lee, United States Patent and Trademark Office IP Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

San Francisco Business Times: Two JOBS Acts are better than one

scientist-eyedropper

Today, the San Francisco Business Times published an op-ed by OncoMed President and CEO Paul Hastings lauding the Jumpstart Our Business Startups Act (JOBS) Act for giving emerging biotech companies a much-needed boost. As Hastings points out, 80-plus companies will have gone public in the last two years with the help of the JOBS Act. As the biotech industry gathers in San Diego next month for the 2014 BIO International Convention, several CEOs in attendance will no Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

BIO Testifies at 21st Century Cures Hearing on PCAST

TheHill

Today, BIO’s Executive Vice President of Health Sara Radcliffe presented testimony to the U.S. House of Representatives Energy and Commerce Subcommittee on Health Hearing. The Hearing focused on the President’s Council of Advisors on Science and Technology (PCAST) Report on Drug Innovation and key issues related to the 21st Century Cures initiative to examine what steps the Committee can take to accelerate the pace of cures in America. Below is a summary: The Challenge of Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,